ARESTIN® + SRPBack

ARESTIN® + SRPBack

ARESTIN® Delivers Therapeutic Levels of Antibiotic With a Microsphere Delivery System1

ARESTIN® Contains Minocycline, a Proven, Broad-Spectrum Antibiotic1

arestin perio scaling root planing handle microspheres

ARESTIN® has a delivery system – minocycline microspheres are administered as a powder to allow for easy placement at the base of the pocket.1

Once inserted in the pocket, contact with gingival crevicular fluid hydrolyzes the bioadhesive microspheres, allowing them to immediately adhere to the surrounding surfaces. This also causes water-filled channels to form inside the microspheres, providing for a sustained release of     minocycline over time.2

ARESTIN® can remain active in the pocket for up to 14 days and does not require removal because it is bioresorbable.1,2


ARESTIN® in Action

Watch ARESTIN® help fight periodontal disease in this animated mechanism of action (MOA) video.

The Active Ingredient in ARESTIN®, Minocycline, Is a Trusted Antimicrobial1

Minocycline achieves inhibitory concentration levels well above those required for common periodontal pathogens and effectively treats the harmful bacteria that cause periodontitis.1 

Minocycline inhibits enzymes and other molecules that destroy elements of the periodontium, including collagen.1

*Two single-blind, Phase III trials comparing ARESTIN® + SRP to SRP alone and SRP + placebo (n=748). SRP was performed for all groups at baseline. ARESTIN® or vehicle was administered to periodontal pockets ≥5 mm in the adjunctive therapy groups at baseline, 3 months, and 6 months. Efficacy was evaluated over 9 months.
 
REFERENCES: 1. ARESTIN® (minocycline hydrochloride) Microspheres, 1 mg. Prescribing Information. Horsham, PA: OraPharma, Inc.; 2011. 2. Williams RC. Medical progress: periodontal disease. New Engl J Med. 1990;322(6):373-380.

How to Administer ARESTIN® 


See how to administer ARESTIN® in three simple steps. 

INDICATION
ARESTIN® (minocycline HCl) Microspheres, 1 mg is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN® may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.

IMPORTANT SAFETY INFORMATION
ARESTIN® should not be used in any patient who has a known sensitivity to minocycline or tetracyclines. The use of drugs of the tetracycline class during tooth development may cause permanent discoloration of the teeth, and therefore should not be used in children or in pregnant or nursing women. Hypersensitivity reactions that included, but were not limited to, anaphylaxis, angioneurotic edema, urticaria, rash, swelling of the face and pruritus have been reported with the use of ARESTIN®. In clinical trials, the most frequently reported nondental treatment-emergent adverse events were headache, infection, flu syndrome and pain.

Please read the Full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

MyArestinTM is a trademark and ARESTIN® is a registered trademark of OraPharma, Inc.

This site is published by OraPharma, Inc., which is solely responsible for its contents. It is intended for visitors from the United States.

Manufactured for OraPharma, Inc. ©OraPharma, Inc. 2013   A-1373-12   01/13